Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Race Oncology Ltd. ( (AU:RAC) ) just unveiled an update.
Race Oncology Ltd has appointed Professor Laurence Hurley, a distinguished oncology drug developer, to its Scientific Advisory Board. Prof Hurley, known for his pioneering work in G-quadruplex targeting drugs, will provide valuable insights into the development of Race’s G4-targeting agents, potentially enhancing the company’s position in the oncology drug market. This move is expected to strengthen Race’s research and development efforts, potentially leading to significant advancements in cancer treatment.
More about Race Oncology Ltd.
Race Oncology Ltd is a company in the pharmaceutical industry, focusing on the development of oncology drugs. The company is known for its work on G-quadruplex targeting drugs, including RCDS1 (E,E-bisantrene) and RC220, which are aimed at treating various cancers.
Average Trading Volume: 369,828
Technical Sentiment Signal: Buy
Current Market Cap: A$684.8M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.